615. Au J, Walker WS, Scott DHT. Withdrawal syndrome after propofol infusion. *Anaesthesia* 1990; 45: 741-2
616. Drummer OH. A fatality due to propofol poisoning. *J Forensic Sci* 1992; 37: 1186-9
617. Chao TC, Lo DST, Chui PPS, et al. The first fatal 2,6-diisopropylphenol (propofol) poisoning in Singapore: a case report. *Forensic Sci Int* 1994; 66: 1-7
618. Ananthanarayan C, Fisher JA. Why was the urine green? *Can J Anaesth* 1995; 42: 87-8
619. Bodenham A, Culank LS, Park GR. Propofol infusion and green urine [letter]. *Lancet* 1987; 2: 740
620. Vincent RD, Syrop CH, Van Voorhis BJ, et al. An evaluation of the effect of anesthetic technique on reproductive success after laparoscopic pronuclear stage transfer: propofol/nitrous oxide versus isoflurane/nitrous oxide. *Anesthesiology* 1995; 82: 352-8
621. Pierce ET, Smalky M, Alper MM, et al. Comparison of pregnancy rates following gamete intrafallopian transfer (GIFT) under general anesthesia with thiopental sodium or propofol. *J Clin Anesth* 1992; 4: 394-8
622. Hatton MQF, Allen MB, Vathenen AS, et al. Does sedation help in fiberoptic bronchoscopy? *BMJ* 1994; 309: 1206-7

Correspondence: Harriet M. Bryson, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

Errata

Vol. 49, No. 2, page 298: In the Tolerability summary, the last sentence should read, 'In the treatment of BPH, adverse effects that were reported significantly more frequently with doxazosin than with placebo included *dizziness* (15.6%), *fatigue* (8%), *oedema* (2.7%), *dyspnoea* (2.6%) and *hypotension* (1.7%).'

page 299: In figure 1, the structures of doxazosin, prazosin and terazosin should be as follows:

Doxazosin

Prazosin

Terazosin

page 314: In table VI, the incidence of hypotension in patients with benign prostatic hypertrophy (BPH) receiving doxazosin should be 1.7%*.

[Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. *Drugs* 1995; 49: 295-320]